EXHIBIT A

Published results of NOPR:
Clinical Impact of Na\(^{18}\) F PET-CT Bone Scintigraphy in Malignancy

Results of investigation defining clinical impact on decision making by referring and interpreting physicians

\(n = 7154 \text{ January 31}^{st} \ 2011 \ - \ \text{January 27}^{th} \ 2012\) \quad \(n = 7794 \text{ January 28}^{th} \ 2012 \ - \ \text{December 31}^{st}, \ 2012\)

~ 50 of the 633 total participating centers performed 50% of the studies

Individual Na F PET-CT bone scintigraphy examinations performed for:
1. Initial staging (IS) \(n = 223\)
2. Defining first osseous metastases (FOM) \(n = 653\)
3. Progressive skeletal metastatic disease (POM) \(n = 236\)

Other malignancies: Bladder, kidney, colorectal, lymphoma

<table>
<thead>
<tr>
<th>Malignancy</th>
<th>IS</th>
<th>FOM</th>
<th>POM</th>
</tr>
</thead>
<tbody>
<tr>
<td>bladder</td>
<td>58.2%</td>
<td>34.7%</td>
<td>19.7%</td>
</tr>
<tr>
<td>kidney</td>
<td>47.1%</td>
<td>26.2%</td>
<td>10.7%</td>
</tr>
<tr>
<td>colorectal</td>
<td>28.3%</td>
<td>13.1%</td>
<td>10.7%</td>
</tr>
<tr>
<td>lymphoma</td>
<td>0%</td>
<td>0%</td>
<td>4.9%</td>
</tr>
</tbody>
</table>

Impact of NaF PET-CT bone scintigraphy on future actions: Avoiding future diagnostic testing

\(77.6\%\) for Initial staging, \(84.5\%\) for First osseous metastases, \(89.4\%\) for Progressive osseous metastases

Published results of NOPR: Clinical Impact of Na\textsuperscript{18} F PET-CT Bone Scintigraphy in Malignancy

Results of investigation defining clinical impact on decision making by referring and interpreting physicians

(n = 7154 January 31\textsuperscript{st} 2011 – January 27\textsuperscript{th} 2012) (n = 7794 January 28\textsuperscript{th} 2012 – December 31\textsuperscript{st}, 2012)

\~ 50 of the 633 total participating centers performed 50% of the studies

Individual Na F PET-CT bone scintigraphy examinations performed for:
1. Initial staging (IS) n=1024
2. Defining first osseous metastases (FOM) n = 1997
3. Progressive skeletal metastatic disease (POM) n = 510

Prostate carcinoma

Impact of Na\textsuperscript{19} F PET-CT bone scintigraphy on future actions: Avoiding future diagnostic testing

Published results of NOPR: Clinical Impact of Na\textsuperscript{18} F PET-CT Bone Scintigraphy in Malignancy

Results of investigation defining clinical impact on decision making by referring and interpreting physicians

(n = 7154 January 31\textsuperscript{st} 2011 – January 27\textsuperscript{th} 2012) (n = 7794 January 28\textsuperscript{th} 2012 – December 31\textsuperscript{st}, 2012)

~ 50 of the 633 total participating centers performed 50% of the studies

Individual Na F PET-CT bone scintigraphy examinations performed for:
1. Initial staging (IS) n = 181
2. Defining first osseous metastases (FOM) n = 781
3. Progressive skeletal metastatic disease (POM) n = 199

Breast carcinoma

Na F PET-CT bone scintigraphy impact on patient management

Published results of NOPR: Clinical Impact of Na\textsuperscript{18} F PET-CT Bone Scintigraphy in Malignancy

Results of investigation defining clinical impact on decision making by referring and interpreting physicians

(n = 7154 January 31\textsuperscript{st} 2011 – January 27\textsuperscript{th} 2012) (n = 7794 January 28\textsuperscript{th} 2012 – December 31\textsuperscript{st}, 2012)

~ 50 of the 633 total participating centers performed 50% of the studies

Individual Na F PET-CT bone scintigraphy examinations performed for:
1. Initial staging (IS) n = 166
2. Defining first osseous metastases (FOM) n = 380
3. Progressive skeletal metastatic disease (POM) n = 0

Impact of NaF PET-CT bone scintigraphy on future actions: Avoiding future diagnostic testing